Teresa Marafioti

List of Publications by Year
in descending order

184 papers	17,140 citations	31976 53 h-index	16650 123 g-index
198 all docs	198 docs citations	198 times ranked	24515 citing authors

#	Article	IF	Citations
1	Burkitt lymphoma with a granulomatous reaction: an M1/Th1â€polarised microenvironment is associated with controlled growth and spontaneous regression. Histopathology, 2022, 80, 430-442.	2.9	8
2	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	7.8	30
3	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. Clinical Cancer Research, 2022, 28, 2657-2668.	7.0	4
4	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	3.1	4
5	A local human VÎ´1 T cell population is associated with survival in nonsmall-cell lung cancer. Nature Cancer, 2022, 3, 696-709.	13.2	39
6	Abstract 6091: Evolutionary characterisation of lung adenocarcinoma pathological subtypes in TRACERx. Cancer Research, 2022, 82, 6091-6091.	0.9	0
7	Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours. Neuroendocrinology, 2021, 111, 465-474.	2.5	15
8	Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Realâ€World Experience from 554 sequential core biopsies from a single centre. European Journal of Haematology, 2021, 106, 267-272.	2.2	9
9	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nature Communications, 2021, 12, 117.	12.8	34
10	Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathologica, 2021, 141, 901-915.	7.7	28
11	Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma. Cancers, 2021, 13, 2137.	3.7	11
12	Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. Science Translational Medicine, 2021, 13, .	12.4	27
13	Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution, 2021, 5, 1033-1045.	7.8	50
14	Thyroid MALT lymphoma: self-harm to gain potential T-cell help. Leukemia, 2021, 35, 3497-3508.	7.2	17
15	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. Cancer Discovery, 2021, 11, 2456-2473.	9.4	74
16	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
17	Using DNA sequencing data to quantify T cell fraction and therapy response. Nature, 2021, 597, 555-560.	27.8	36
18	Axillary lymphadenopathy in a high-risk breast screening patient following the COVID-19 vaccine: a diagnostic conundrum. BJR|case Reports, 2021, 7, 20210063.	0.2	0

#	Article	IF	Citations
19	Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. , 2021, 9, e001519.		10
20	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	16.8	126
21	Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations. International Journal of Experimental Pathology, 2021, 102, 45-50.	1.3	1
22	Aberrant chromatin landscape following loss of the H3.3 chaperone Daxx in haematopoietic precursors leads to Pu.1-mediated neutrophilia and inflammation. Nature Cell Biology, 2021, 23, 1224-1239.	10.3	10
23	Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells. Immunity, 2020, 52, 151-166.e6.	14.3	130
24	Antitumor activity without on-target off-tumor toxicity of GD2â€"chimeric antigen receptor T cells in patients with neuroblastoma. Science Translational Medicine, 2020, 12, .	12.4	108
25	CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nature Cancer, 2020, 1, 1153-1166.	13.2	97
26	Multiplex immunohistochemistry in lymphoma pathology: a research tool for study of the immune microenvironment. Diagnostic Histopathology, 2020, 26, 407-420.	0.4	2
27	Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. Cancer Discovery, 2020, 10, 1489-1499.	9.4	60
28	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6.	0.6	0
29	Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program. Infectious Agents and Cancer, 2020, 15, 28.	2.6	30
30	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 2020, 26, 1054-1062.	30.7	181
31	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
32	Intratumoural (IT) evolutionary landscape of high-risk prostate cancer and outcome: The PROGENY (PROstate cancer GENomic heterogeneitY) study of genomic and immune parameters.. Journal of Clinical Oncology, 2020, 38, e17500-e17500.	1.6	0
33	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. OncoImmunology, 2019, 8, e1617588.	4.6	41
34	THU-485-Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e374-e375.	3.7	0
35	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell, 2019, 36, 35-50.e9.	16.8	179
36	Novel markers in pediatric-type follicular lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 771-779.	2.8	22

#	Article	IF	Citations
37	Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. Blood, 2019, 134, 1415-1429.	1.4	148
38	Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. British Journal of Cancer, 2019, 120, 1033-1036.	6.4	66
39	Neoantigen-directed immune escape in lung cancer evolution. Nature, 2019, 567, 479-485.	27.8	639
40	Role of Epstein-Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature. Haematologica, 2019, 104, e269-e273.	3.5	13
41	PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity. Immunotherapy, 2019, 11, 585-590.	2.0	6
42	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. British Journal of Cancer, 2019, 120, 294-300.	6.4	25
43	ConCORDe-Net: Cell Count Regularized Convolutional Neural Network for Cell Detection in Multiplex Immunohistochemistry Images. Lecture Notes in Computer Science, 2019, , 667-675.	1.3	14
44	Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).. Journal of Clinical Oncology, 2019, 37, TPS5090-TPS5090.	1.6	4
45	Molecular characterization of the tumour microenvironment in neuroendocrine malignancy.. Journal of Clinical Oncology, 2019, 37, 4107-4107.	1.6	0
46	Clonal evolution in the transition from cutaneous disease to acute leukemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm. Haematologica, 2018, 103, e196-e199.	3.5	8
47	ADCT-402, a PBD dimerâ€"containing antibody drug conjugate targeting CD19-expressing malignancies. Blood, 2018, 131, 1094-1105.	1.4	115
48	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell, 2018, 33, 649-663.e4.	16.8	448
49	THUR 220â€...To c or not to c. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A32.1-A32.	1.9	0
50	Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. Journal of Experimental Medicine, 2018, 215, 2748-2759.	8.5	34
51	LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L. Nature Communications, 2018, 9, 3910.	12.8	81
52	Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 749-757.	2.8	6
53	Can somatic GATA2 mutation mimic germ line GATA2 mutation?. Blood Advances, 2018, 2, 904-908.	5.2	15
54	Functional immune characterization of HIV-associated non-small-cell lung cancer. Annals of Oncology, 2018, 29, 1486-1488.	1.2	10

#	Article	IF	Citations
55	Pan-cancer deconvolution of tumour composition using DNA methylation. Nature Communications, 2018, 9, 3220.	12.8	205
56	Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial. Blood, 2018, 132, 1627-1627.	1.4	6
57	Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: The Blueprint-HCC study.. Journal of Clinical Oncology, 2018, 36, 91-91.	1.6	2
58	Abstract 3812: A best in class anti-CD38 antibody with antitumor and immune-modulatory properties. , 2018, , .		0
59	Cytotoxic CD4+ Cells in Chronic Lymphocytic Leukaemia: An Extended Immunophenotypic Analysis Examining Their Association with Cytomegalovirus Serostatus and Similarities with Cytotoxic CD8+ Cells. Blood, 2018, 132, 3130-3130.	1.4	0
60	Analysis of T-Cell Receptor Beta-Constant Region Expression for Rapid Assessment of T-Cell Clonality. Blood, 2018, 132, 2867-2867.	1.4	1
61	Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review. Leukemia and Lymphoma, 2017, 58, 2403-2418.	1.3	15
62	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	14.3	323
63	Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA. Blood, 2017, 129, 3126-3129.	1.4	23
64	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	27.8	1,287
65	Tracking the Evolution of Nonâ€"Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	27.0	1,786
66	Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood, 2017, 130, 323-327.	1.4	69
67	Emergence of Bruton's tyrosine kinaseâ€negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. European Journal of Haematology, 2017, 99, 378-380.	2.2	11
68	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	28.9	968
69	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Annals of Oncology, 2017, 28, 2472-2480.	1.2	45
70	Targeting the T cell receptor Î²-chain constant region for immunotherapy of T cell malignancies. Nature Medicine, 2017, 23, 1416-1423.	30.7	196
71	Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet, The, 2017, 390, 2343-2345.	13.7	148
72	Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies. , 2017, , .		1

#	Article	IF	Citations
73	Immune-infiltrate characterization in localized osteosarcoma patients treated within protocol ISG-OS1.. Journal of Clinical Oncology, 2017, 35, 11025-11025.	1.6	1
74	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget, 2017, 8, 111836-111846.	1.8	44
75	Cell cycle status in <scp>AML</scp> blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment. British Journal of Haematology, 2016, 174, 275-279.	2.5	7
76	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood, 2016, 128, 1101-1111.	1.4	115
77	Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. British Journal of Haematology, 2016, 172, 32-43.	2.5	27
78	ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimerâ€"Containing Antibodyâ€"Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics, 2016, 15, 2709-2721.	4.1	102
79	Paediatric follicular lymphoma. Diagnostic Histopathology, 2016, 22, 6-10.	0.4	1
80	LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. Journal of Immunology, 2016, 196, 2085-2094.	0.8	49
81	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	12.6	2,445
82	VEGFA- a New Therapeutic Target in CNS Leukemia. Blood, 2016, 128, 911-911.	1.4	6
83	Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM).. Journal of Clinical Oncology, 2016, 34, TPS9599-TPS9599.	1.6	0
84	Targeting T-Cell Receptor Î²-Constant Domain for Immunotherapy of T-Cell Malignancies. Blood, 2016, 128, 811-811.	1.4	0
85	BRAF^V^{600E} mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. British Journal of Haematology, 2015, 170, 282-285.	2.5	7
86	Deep in vivo photoacoustic imaging of mammalian tissues using a tyrosinase-based genetic reporter. Nature Photonics, 2015, 9, 239-246.	31.4	362
87	Brutonâ€™s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 229-235.	2.8	23
88	Diagnostic Pitfalls in â€œLow-Grade Lymphomaâ€•of the Orbit and Lacrimal Gland. Orbit, 2015, 34, 206-211.	0.8	4
89	Diffuse large B-cell lymphoma and Burkitt lymphoma. Diagnostic Histopathology, 2015, 21, 391-399.	0.4	0
90	Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Blood, 2015, 126, 1559-1559.	1.4	6

#	Article	IF	Citations
91	Cutaneous T Cell Lymphoma Expresses Immunosuppressive CD80 (B7-1) Cell Surface Protein in a STAT5-Dependent Manner. Journal of Immunology, 2014, 192, 2913-2919.	0.8	27
92	A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood, 2014, 124, 1277-1287.	1.4	308
93	Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas. Diagnostic Pathology, 2014, 9, 144.	2.0	21
94	Intracellular TCR-signaling Pathway. American Journal of Surgical Pathology, 2014, 38, 1349-1359.	3.7	19
95	The number and growth pattern of plasmacytoid dendritic cells vary in different types of reactive lymph nodes: an immunohistochemical study. Human Pathology, 2013, 44, 1003-1010.	2.0	18
96	Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. Histopathology, 2013, 62, 860-875.	2.9	32
97	CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica, 2013, 98, 1250-1258.	3.5	56
98	<scp>BRAF</scp> V600E mutationâ€specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. British Journal of Haematology, 2013, 162, 848-851.	2.5	36
99	Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of <scp>IRTA</scp>1 and Tâ€bet as positive markers. Histopathology, 2013, 63, 482-498.	2.9	30
100	Ultraâ€deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. Journal of Pathology, 2013, 231, 424-432.	4.5	93
101	ALDH, CA I, and CD2AP. American Journal of Clinical Pathology, 2012, 137, 30-38.	0.7	9
102	Follicular Peripheral T-cell Lymphoma Expands the Spectrum of Classical Hodgkin Lymphoma Mimics. American Journal of Surgical Pathology, 2012, 36, 1636-1646.	3.7	79
103	Immunohistochemical detection of CD3 in T-cell lymphomas: superior sensitivity of rabbit monoclonal 2GV6 antibody compared to mouse monoclonal F7Â·2Â·38 antibody. Journal of Histotechnology, 2012, 35, 175-179.	0.5	2
104	Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood, 2012, 119, 5795-5806.	1.4	99
105	Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia, 2012, 26, 1053-1063.	7.2	163
106	Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and nonâ€haematopoietic tumours using a newly developed rabbit monoclonal antibody. Histopathology, 2012, 61, 33-46.	2.9	32
107	The Ataxia Telangiectasia Nude Mouse with No Risk of Thymoma: A Model to Investigate Tumour Development of B Cell and Myeloid Origin Associated with ATM Loss. Blood, 2012, 120, 1320-1320.	1.4	0
108	APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood, 2011, 117, 890-901.	1.4	50

#	Article	IF	Citations
109	Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood, 2011, 118, 3062-3071.	1.4	32
110	Rituximab in combination with CODOXâ€M/IVAC: a retrospective analysis of 23 cases of nonâ€HIV related Bâ€cell nonâ€Hodgkin lymphoma with proliferation index >95%. British Journal of Haematology, 2011, 152, 175-181.	2.5	29
111	Heterogeneous expression of B cellâ€associated markers in follicular lymphoma. Histopathology, 2011, 58, 633-636.	2.9	0
112	Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennertâ€™s personal archive. Histopathology, 2011, 59, 679-691.	2.9	51
113	Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennertâ€™s lymphoma nowadays?. Histopathology, 2011, 59, 1173-1182.	2.9	47
114	The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica, 2010, 95, 432-439.	3.5	99
115	Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 561-572.	1.2	24
116	Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood, 2010, 115, 1226-1237.	1.4	285
117	Induction of p53 and up-regulation of the p53 pathway in the human 5qâˆ’ syndrome. Blood, 2010, 115, 2721-2723.	1.4	65
118	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. Haematologica, 2010, 95, 2056-2062.	3.5	28
119	The expression of Bclâ€2 by proliferating cells varies in different categories of Bâ€cell lymphoma. Histopathology, 2010, 56, 617-626.	2.9	4
120	Immune Phenotype Predicts Risk for Posttransplantation Squamous Cell Carcinoma. Journal of the American Society of Nephrology: JASN, 2010, 21, 713-722.	6.1	82
121	Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?. Haematologica, 2010, 95, 670-673.	3.5	17
122	Regulatory T-Cell Depletion in Angioimmunoblastic T-Cell Lymphoma. American Journal of Pathology, 2010, 177, 570-574.	3.8	26
123	Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. Methods, 2010, 52, 352-358.	3.8	19
124	Epigenetic Silencing of a Proapoptotic Cell Adhesion Molecule, the Immunoglobulin Superfamily Member IGSF4, by Promoter CpG Methylation Protects Hodgkin Lymphoma Cells from Apoptosis. American Journal of Pathology, 2010, 177, 1480-1490.	3.8	22
125	Characterization of c-Maf Transcription Factor in Normal and Neoplastic Hematolymphoid Tissue and Its Relevance in Plasma Cell Neoplasia. American Journal of Clinical Pathology, 2009, 132, 361-371.	0.7	14
126	BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. British Journal of Haematology, 2009, 144, 716-725.	2.5	46

#	Article	IF	Citations
127	Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. British Journal of Haematology, 2009, 146, 86-90.	2.5	25
128	Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Modern Pathology, 2009, 22, 753-761.	5.5	65
129	Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues. Pathology Research and Practice, 2009, 205, 781-788.	2.3	21
130	Peripheral T-cell Lymphomas With a Follicular Growth Pattern are Derived From Follicular Helper T Cells (TFH) and may Show Overlapping Features With Angioimmunoblastic T-cell Lymphomas. American Journal of Surgical Pathology, 2009, 33, 682-690.	3.7	189
131	Peripheral Tâ€cell lymphoma with a follicular growth pattern: derivation from follicular helper T cells and relationship to angioimmunoblastic Tâ€cell lymphoma. British Journal of Haematology, 2008, 143, 439-441.	2.5	30
132	Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood, 2008, 111, 3778-3792.	1.4	204
133	Labeling of Multiple Cell Markers and mRNA Using Automated Apparatus. Applied Immunohistochemistry and Molecular Morphology, 2008, 16, 371-381.	1.2	12
134	Dysregulation of Pax5 Activity Contributes to the Extinction of the B-Cell Phenotype in Reed-Sternberg Cells. Blood, 2008, 112, 517-517.	1.4	1
135	Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica, 2007, 92, 1059-1066.	3.5	142
136	Detection of Genetic Alterations by ImmunoFISH Analysis of Whole Cells Extracted from Routine Biopsy Material. Journal of Molecular Diagnostics, 2007, 9, 479-489.	2.8	19
137	Microrna expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. International Journal of Cancer, 2007, 121, 1156-1161.	5.1	361
138	Selective loss of Bâ€cell phenotype in lymphocyte predominant Hodgkin lymphoma. Journal of Pathology, 2007, 213, 429-440.	4.5	22
139	Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. British Journal of Haematology, 2007, 136, 829-832.	2.5	52
140	B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. Journal of Clinical Investigation, 2007, 117, 2602-2610.	8.2	37
141	Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood, 2006, 108, 1013-1020.	1.4	75
142	Transmembrane adaptor molecules: a new category of lymphoid-cell markers. Blood, 2006, 107, 213-221.	1.4	39
143	Jaw1/LRMP, a germinal centre-associated marker for the immunohistological study of B-cell lymphomas. Journal of Pathology, 2006, 209, 454-463.	4.5	40
144	Loss of CD19 expression in B-cell neoplasms. Histopathology, 2006, 48, 239-246.	2.9	42

#	Article	IF	Citations
145	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. International Journal of Cancer, 2006, 118, 3161-3166.	5.1	44
146	Follicular lymphoma with trisomy 18 exhibiting loss of BCL-2 expression on transformation to a large cell lymphoma. Journal of Clinical Pathology, 2006, 60, 1061-1064.	2.0	3
147	ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2006, 12, 726-734.	7.0	50
148	The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 810-810.	1.4	0
149	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica, 2006, 91, 467-74.	3.5	70
150	The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Haematologica, 2006, 91, 772-80.	3.5	37
151	Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood, 2005, 105, 3979-3986.	1.4	111
152	The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. British Journal of Haematology, 2005, 128, 333-342.	2.5	69
153	Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia, 2005, 19, 856-861.	7.2	23
154	The FOXP1 Transcription Factor is Expressed in the Majority of Follicular Lymphomas but is Rarely Expressed in Classical and Lymphocyte Predominant Hodgkinâ€™s Lymphoma. Journal of Molecular Histology, 2005, 36, 249-256.	2.2	25
155	Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. British Journal of Haematology, 2004, 124, 519-533.	2.5	23
156	Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells. British Journal of Haematology, 2004, 127, 335-343.	2.5	30
157	Histopathology of B-cell chronic lymphocytic leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 807-826.	2.2	6
158	Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood, 2004, 103, 188-193.	1.4	59
159	ZAP-70 Expression in Human B cells: Analysis of Normal Cells and Acute Lymphoblastic Leukemia (ALL) Cells with Pro/Pre B Phenotype.. Blood, 2004, 104, 4443-4443.	1.4	0
160	Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. Haematologica, 2004, 89, 957-64.	3.5	26
161	Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkin's disease. British Journal of Haematology, 2003, 120, 671-678.	2.5	13
162	Primary Mediastinal B-Cell Lymphoma. American Journal of Pathology, 2003, 162, 243-253.	3.8	160

#	Article	IF	Citations
163	Expression of B-Lymphocyte-Associated Transcription Factors in Human T-Cell Neoplasms. American Journal of Pathology, 2003, 162, 861-871.	3.8	37
164	Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood, 2003, 102, 2868-2876.	1.4	89
165	Immunoglobulin Gene Rearrangement Analysis in Composite Hodgkin Disease and Large B-Cell Lymphoma: Evidence for Receptor Revision of Immunoglobulin Heavy Chain Variable Region Genes in Hodgkin-Reed-Sternberg Cells?. Diagnostic Molecular Pathology, 2002, 11, 2-8.	2.1	46
166	Tyrosine phosphorylation in human lymphomas. The Histochemical Journal, 2002, 34, 545-552.	0.6	4
167	Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology, 2002, 41, 482-509.	2.9	75
168	Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood, 2001, 97, 3191-3196.	1.4	71
169	Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood, 2001, 97, 496-501.	1.4	264
170	Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Journal of Clinical Pathology, 2000, 53, 188-193.	1.9	81
171	A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood, 2000, 95, 2084-2092.	1.4	409
172	Acute Reaction to Dipyridamole during Myocardial Scintigraphy. New England Journal of Medicine, 1999, 340, 394-394.	27.0	12
173	Clonality of Reedâ€“Sternberg Cells in Hodgkin's Disease. New England Journal of Medicine, 1999, 340, 394-395.	27.0	20
174	Reduced phagocytosis of apoptotic cells in malignant lymphoma. International Journal of Cancer, 1998, 75, 675-679.	5.1	11
175	L&H Cells in Lymphocyte-Predominant Hodgkin's Disease. New England Journal of Medicine, 1998, 338, 763-765.	27.0	12
176	Origin of Nodular Lymphocyte-Predominant Hodgkin's Disease from a Clonal Expansion of Highly Mutated Germinal-Center B Cells. New England Journal of Medicine, 1997, 337, 453-458.	27.0	311
177	Disappearance of the Epstein-Barr virus in a relapse of Hodgkin's disease. , 1997, 182, 475-479.		34
178	CUTANEOUS AGGRESSIVE OSTEOBLASTOMA. International Journal of Dermatology, 1996, 35, 504-505.	1.0	5
179	Immunoglobulin V Genes in Reedâ€“Sternberg Cells. New England Journal of Medicine, 1996, 334, 404-406.	27.0	15
180	Focal lymphocytic aggregates in chronic hepatitis C: Occurrence, immunohistochemical characterization, and relation to markers of autoimmunity. Hepatology, 1995, 22, 389-394.	7.3	1

#	Article	IF	Citations
181	Amyotrophic choreo-acanthocytosis: A neuropathological and immunocytochemical study. Italian Journal of Neurological Sciences, 1993, 14, 49-54.	0.1	8
182	Coexistence of growth hormone-secreting pituitary adenoma and intracranial meningioma: A case report and review of the literature. Journal of Endocrinological Investigation, 1993, 16, 703-708.	3.3	43
183	Mucin histochemistry and lectin binding sites in intestinal metaplasia of the urinary bladder. Histopathology, 1990, 17, 219-223.	2.9	8
184	Epidural spinal meningioma. Role of magnetic resonance in differential diagnosis. Acta Neurochirurgica, 1990, 107, 70-73.	1.7	21